(PharmaNewsWire.Com, March 07, 2018 ) Insomnia has become more common in the society as today's lives become more fast-paced and stressful. Also, the prevalence of insomnia has recorded a tremendous surge in the recent past. To elaborate further, Market Research Hub (MRH) has publicized a new study titled "Insomnia Market - Global Industry Analysis, size, share, growth, trends, and Forecast 2017 – 2026" to its massive online repository. According to the research, the global market for insomnia will register an impressive growth during the period 2017 to 2026. Apart from that, demand for insomnia therapeutics will witness a tremendous rise on the back of growing geriatric population, and rising stress level among the urban population.
Presently, in order to improve insomnia therapeutics, there has been a growing emphasis on developing novel sleep-inducing medical devices along with new technologies. However, manufacturers have developed a series of drugs such as tricyclic antidepressants, zolpidem, trazodone, zaleplon and benzodiazepines, which are useful for short-term treatment of insomnia. Considering the global demand for these drugs and improvements in the market, revenues from the market will reach roughly US$ 4,000 Mn by 2026-end.
From a geographical point of view, North America has been anticipated to remain the largest market for insomnia, in terms of revenues. The market in this region is projected to record the highest CAGR through 2026. As the title of the report suggests, the report delivers forecasts on the global insomnia market, and examines the market in detail, providing important dynamics affecting the market expansion. For a clear understanding of the market, the report has been categorized into treatment type, sales channel and country-wise segmentation.
It has been analyzed in the study that Benzodiazepines will be continued as the important treatment method for insomnia, in terms of revenues. However, devices for the treatment of insomnia are expected to arise as the fastest selling treatment type for insomnia through 2026.
As the report concludes, the vendor landscape section is also provided which throws light on the chief player's dominant in this market. This particular chapter offers insights based on SWOT analysis, key developments, key financials, company overview, and product overview. Key companies profiled by TMR's report include Pernix Therapeutics Holdings, Inc., Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, Merck & Co Company, and Mylan N.V.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
